Relmada Therapeutics Inc Asset Resilience Ratio
Relmada Therapeutics Inc asset resilience ratio. Relmada Therapeutics Inc (RLMD) has an Asset Resilience Ratio of 95.25% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Relmada Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Relmada Therapeutics Inc (2019–2025)
Asset resilience ratio of Relmada Therapeutics Inc from 2019 to 2025. This chart shows how Relmada Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of Relmada Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Relmada Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Relmada Therapeutics Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $224.19 Million | 95.25% |
| Total Liquid Assets | $224.19 Million | 95.25% |
Asset Resilience Insights
- Very High Liquidity: Relmada Therapeutics Inc maintains exceptional liquid asset reserves at 95.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Relmada Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Relmada Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Relmada Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Relmada Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Relmada Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 95.22% | $89.51 Million | $94.00 Million | +5.62pp |
| 2024-12-31 | 89.60% | $41.05 Million | $45.82 Million | -4.95pp |
| 2023-12-31 | 94.55% | $92.23 Million | $97.55 Million | +1.07pp |
| 2022-12-31 | 93.47% | $142.93 Million | $152.91 Million | +18.49pp |
| 2021-12-31 | 74.99% | $167.47 Million | $223.33 Million | -21.97pp |
| 2020-12-31 | 96.96% | $114.60 Million | $118.19 Million | +28.52pp |
| 2019-12-31 | 68.44% | $80.16 Million | $117.14 Million | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more